A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer

Trial Profile

A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AVANTI
  • Most Recent Events

    • 11 Oct 2016 Results (n=2135) of a pooled analysis from ML21165, AVANTI and AVAREG studies assessing real-world effectiveness and safety in clinically important subgroups, presented at the 41st European Society for Medical Oncology Congress.
    • 12 Dec 2015 Status changed from active, no longer recruiting to recruiting, as per results presented at the 38th Annual San Antonio Breast Cancer Symposium.
    • 12 Dec 2015 Interim results presented at the 38th Annual San Antonio Breast Cancer Symposium (n = 2168).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top